louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06909175: Comparing Portal Vein Assessment by Intraoperative Doppler and Transesophageal Echocardiography
Official title: Comparing Transesophageal Echocardiography and Trans Abdominal Doppler for Portal Vein Assessment in Living Donor Liver Transplantation
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Chronic Liver Disease
Lead sponsor: Institute of Liver and Biliary Sciences, India
Sponsor class: OTHER
First posted: 2025-04-03
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Chronic liver disease

Brief summary: Liver transplantation is usually associated with hemodynamic instability. TEE allows for a real time monitoring of cardiac structures and has become a standard of care for liver transplant patients. Society of cardiovascular anaesthesia and American society of anaesthesiologists recommends use of TEE in non-cardiac surgery patients with hemodynamic instability. Also, society for advancement of transplant anaesthesia (SATA) has suggested that TEE usage in cases of liver transplant is safe, effective and improves outcomes. TEE can also provide vital information relating to non-cardiac structures including liver, spleen, kidneys, portal vein, hepatic vein and other major vessels. As of now standard protocol is to do the transabdominal doppler for the assessment of portal vein after the liver graft implantation. Hence, the aim of our study is to compare the transesophageal echocardiography and transabdominal Doppler for assessing portal vein in living donor liver transplantation.

Detailed description: Data from all patients who underwent live donor liver transplant surgery at Institute of Liver and Biliary Sciences, New Delhi and in whom TEE probe was inserted will be collected and analysed.

Eligibility criteria: Inclusion Criteria:

* All patients who have undergone Live donor liver transplant, Age \> 18 years

Exclusion Criteria:

* Required data is not available

Primary outcomes:
measure: To compare the portal vein flow velocity using transesophageal echocardiography and transabdominal Doppler during live donor liver transplant surgery.
timeFrame: intraoperative period
Secondary outcomes:
measure: any TEE related complication
timeFrame: intraoperative period
Other outcomes:
Locations:
Study officials:
affiliation: Institute of Liver and Biliary Sciences
name: Gaurav Sindwani, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05446675: Endoscopic eTEP Versus Open Rives-Stoppa
Official title: Single-Center Observational Study With Comparison of Endoscopic Extended-View Totally Extraperitoneal Prosthesis (eTEP) Versus Open Rives-Stoppa Repair as a Treatment of Midline Abdominal Wall Hernias With Rectus Diastasis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hernia, Ventral
Rectus Diastasis
Keywords: eTEP
Retromuscular
Minimally invasive
Endoscopic
Hernia
Rectus diastasis
Rives-Stoppa
Lead sponsor: AZ Alma
Sponsor class: OTHER
First posted: 2022-07-07
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants who underwent repair for their midline abdominal wall hernias alongside rectus abdominis diastasis.

Brief summary: Observational cohort study (partially retrospective, partially prospective) comparing the endoscopic extended totally extraperitoneal prosthesis (eTEP) repair for midline abdominal hernias to open Rives-Stoppa repair (control).

Detailed description: See included study protocol. Included patients will be registered to the European Hernia Society (EHS) registry.

Eligibility criteria: Inclusion Criteria:

Group 1 (eTEP):

* Participants who underwent an eTEP procedure in the investigators' center
* Preoperative existence of one or more midline abdominal wall hernias
* Preoperative existence of rectus abdominis diastasis

Group 2 (Rives-Stoppa, control group):

- Participants who underwent an open Rives-Stoppa (midline repair with sublay mesh) in the investigators' center

Exclusion Criteria:

Group 1 (eTEP):

* Preoperative absence of midline abdominal wall hernias
* Preoperative absence of rectus abdominis diastasis
* Intraoperative performance of transverse abdominis release (TAR)
* Intraoperative inguinal hernia repair

Group 2 (Rives-Stoppa, control group):

* Intraoperative performance of transverse abdominis release (TAR)
* Intraoperative performance of anterior component separation
* Intraoperative inguinal hernia repair

Primary outcomes:
measure: Length of hospital stay
timeFrame: From the date of operation until the date of discharge from the hospital, assessed up to 30 days.
measure: Postoperative pain management
timeFrame: From the end of surgery (moment of the end of operation) until the date of discharge from the hospital, assessed up to 30 days.
Secondary outcomes:
measure: Intraoperative complications
timeFrame: During surgery
measure: Postoperative complications
timeFrame: After discharge until 30 days postoperative
Other outcomes:
Locations:
city: Eeklo
country: Belgium
facility: AZ Alma
state: Oost-Vlaanderen
Study officials:
affiliation: AZ Alma
name: Sam Kinet, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04062175: Efficacy of Adding Azithromycin to Cephalosporin Before Cesarean Delivery
Official title: Efficacy of Adding Azithromycin to Cephalosporin for the Prophylaxis Against Infectious Morbidity Following Cesarean Delivery in High Risk Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Wound Sepsis
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2019-08-20
Enrollment: 144
Sex: FEMALE
Minimum age (years): 17
Maximum age (years): 39
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: efficacy of adding azithromycin to cephalosporin before cesarean delivery

Detailed description: efficacy of adding azithromycin to cephalosporin for the prophylaxis against infectious morbidity following cesarean delivery in high risk women

Eligibility criteria: Inclusion Criteria:

* age between 17 and 39 years
* gestaional age between 37 to 42 weeks
* elective cesarean delivery
* obese women

Exclusion Criteria:

* diabetic women on corticosteroids
* intraopertaive complication in previous section
* history of septic woun
* prelabour rupture of membrane \>12 hours

Primary outcomes:
measure: % of women with wound infection
timeFrame: after 14 days post cesarean delivery
Secondary outcomes:
measure: % of women with postpartum endometritis
timeFrame: after 14 days post cesarean delivery
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams maternity hospital
Study officials:
affiliation: AinShams university ,egypt el abbasia
name: Reda Mokhtar, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03128775: Nudging Students Towards Healthy Diet and Physical Activity to Prevent Obesity
Official title: School Randomized Factorial Trial for Nudging Students Towards Healthy Diet and Physical Activity to Prevent Obesity: a Study Protocol
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Obesity
Lead sponsor: Rio de Janeiro State University
Sponsor class: OTHER
Collaborators: name: Oswaldo Cruz Foundation
name: University of Copenhagen
name: Universidade Federal do Rio de Janeiro
First posted: 2017-04-25
Enrollment: 0
Sex: ALL
Minimum age (years): 9
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: PAAPPAS Nudge is a randomized community-based, school-based trial designed to promote healthful choices in a low-income scenario, with will be held in 2018 school-year in 18 municipal public schools in the municipality of Duque de Caxias, metropolitan area of Rio de Janeiro, Brazil (http://duquedecaxias.rj.gov.br/portal/). All students from the 5th and 6th grade from the 18 selected schools will be invited to participate to the study.

The study design will be of the factorial type, with 4 group arms:

A) Group 1: control (without any activity); B) Group 2: will receive educational activities in the classroom; C) Group 3: will receive changes in the school environment (nudge strategies); D) Group 4: will receive educational activities and changes in the school environment.
Primary purpose: PREVENTION

Brief summary: The objective of the present study is to estimate the effect of nudging proposals on the students' Body Mass Index, based on changes made in the school environment. This is a factorial randomized community trial, which will be conducted in 18 public schools in the city of Duque de Caxias, RJ.


Eligibility criteria: Inclusion Criteria:

5th and 6th grades students consent form signed by parents/tutors

Exclusion Criteria:

pregnant girls

Primary outcomes:
measure: Body mass Index (BMI)
timeFrame: 1 year
Secondary outcomes:
measure: body fat percentage
timeFrame: 1 year
Other outcomes:
Locations:
city: Duque de Caxias
country: Brazil
facility: 18 Schools of Metropolitan Area
state: Rio de Janeiro
Study officials:
References:
Clinical trial NCT00006275: Study of Topical Calcitriol in Children With Psoriasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Psoriasis
Keywords: dermatologic disorders
psoriasis
rare disease
Lead sponsor: Office of Rare Diseases (ORD)
Sponsor class: NIH
Collaborators: name: Boston University
First posted: 2000-09-12
Enrollment: 20
Sex: ALL
Minimum age (years): 4
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: OBJECTIVES:

I. Determine the therapeutic efficacy and safety of topical calcitriol in children with psoriasis.

Detailed description: PROTOCOL OUTLINE: Patients apply topical calcitriol in petrolatum on a psoriatic lesion daily. Patients also apply petrolatum without calcitriol to another psoriatic lesion daily.

Patients have both lesions photographed prior to therapy, monthly during therapy, and at the completion of therapy. Lesions are assessed weekly for 1 month and then every 2 weeks while on study. Blood samples are collected every 1 to 2 months and urine samples are collected every 2 weeks while on study.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Diagnosis of psoriasis At least 2 lesions with area at least 30-50 cm2

--Prior/Concurrent Therapy--

No other concurrent therapy for psoriasis No concurrent calcium supplements greater than 1,000 mg/day No concurrent prednisone or other drugs affecting serum or urine calcium levels

--Patient Characteristics--

Renal: No high blood or urinary calcium levels

Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Boston University
name: Michael F. Holick
role: STUDY_CHAIR
References:
Clinical trial NCT00510575: Surgical Outcomes Using Variable Rod Diameters in the Treatment of Idiopathic Scoliosis
Official title: Surgical Outcomes Using Variable Rod Diameters in the Treatment of Idiopathic Scoliosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Scoliosis
Keywords: Juvenile Scoliosis
Adolescent Scoliosis
Scoliosis Management
Spinal Fusion
Scoliosis instrumentation
Juvenile or Adolescent Idiopathic Scoliosis
Lead sponsor: Shriners Hospitals for Children
Sponsor class: OTHER
First posted: 2007-08-02
Enrollment: 300
Sex: ALL
Minimum age (years): 11
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There are two rod sizes routinely used for the correction of juvenile and adolescent idiopathic scoliosis, 5.5mm and 6.35mm, typically stainless steel. Currently there is no scientific evidence supporting the superiority of one size rod relative to the other. This study will evaluate the amount of radiographic correction obtained using the 5.5mm versus the 6.35mm spinal instrumentation rods.

Detailed description: For the correction of Juvenile and Adolescent idiopathic scoliosis, companies offer and surgeons use varying rod sizes not based on scientific evidence, but because of personal preference, availability and company loyalty. To date there has been no literature evaluating the benefit or harm of one rod size versus the other. Our dual-arm prospective study will evaluate the amount of radiographic correction obtained using the 5.5mm versus the 6.35mm stainless steel instrumentation rods. These are both standard rods used in the community for this particular procedure, thus no additional risk exists for the patient. The results of this study will help guide surgeons in their decision making process when faced with the multitude of options offered by implant manufactures.

Comparison(s): 5.5mm stainless steel spinal rod versus 6.35mm stainless steel spinal rod for correction of juvenile and idiopathic scoliosis curves.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of Juvenile or Adolescent Idiopathic Scoliosis
* Anticipated spinal fusion surgery

Exclusion Criteria:

* Individuals younger than 11 years and older than 18 years
* Individuals with scoliosis carrying additional diagnoses of illness.

Primary outcomes:
measure: Radiographic measurements of curve angles and balance.
timeFrame: Pre-operatively, 6 wks post-op, 1 & 2 year post-op.
Secondary outcomes:
measure: Scoliosis Research Society-30 (SRS-30) questionnaire
timeFrame: Pre-operatively, 6 wks post-op, 1 & 2 year post-op.
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Shriners Hospitals for Children - Los Angeles
state: California
Study officials:
affiliation: Shriners Hospitals for Children - Los Angeles
name: Norman Otsuka, MD
role: STUDY_DIRECTOR
affiliation: Shriners Hospitals for Children - Los Angeles
name: Richard Bowen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06711575: Model-informed Individualized Treatment of Anti-Infective Drugs in Patients With Spinal Infections
Official title: Model-informed Individualized Treatment of Anti-Infective Drugs in Patients With Spinal Infections
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Infectious Diseases of Spine
Lead sponsor: Shandong University
Sponsor class: OTHER
Collaborators: name: Shandong Public Health Clinical Center
First posted: 2024-12-02
Enrollment: 300
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with suspected/confirmed spinal infections who are undergoing anti-infective drug therapy.

Brief summary: The purpose of this study is to describe the population pharmacokinetic characteristics in patients with suspected/confirmed spinal infections who are undergoing anti-infective drug therapy, and to evaluate effectiveness and safety of these drugs.


Eligibility criteria: Inclusion Criteria:

* Patients with suspected/confirmed spinal infections who are undergoing anti-infective drug therapy.

Exclusion Criteria:

* Pregnant/lactating women.
* There are other factors that the researchers think are not suitable for inclusion

Primary outcomes:
measure: Clearance (L/h)
timeFrame: Through study completion, an average of 30 days
measure: Volume of Distribution (L)
timeFrame: Through study completion, an average of 30 days
Secondary outcomes:
measure: the ratio of the area under the concentration-time curve from 0 to 24 hours
timeFrame: Through study completion, an average of 30 days
measure: erythrocyte sedimentation rate
timeFrame: Through study completion, an average of 30 days
measure: Adverse events
timeFrame: Through study completion, an average of 30 days
Other outcomes:
Locations:
city: Jinan
country: China
facility: Shandong Public Health Clinical Center
Study officials:
affiliation: Shandong University
name: Wei Zhao, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06047275: HCV Microfluidic Diagnostics
Official title: Development of Point-of-care and Wearable Sensors for Hepatitis C Diagnostics
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatitis C
Lead sponsor: University of Hull
Sponsor class: OTHER
Collaborators: name: Hull University Teaching Hospitals NHS Trust
First posted: 2023-09-21
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with potential Hep C

Brief summary: Hepatitis C diagnostic devices have been developed at the University of Hull to detect and quantify the Hepatitis C virus in patients' plasma and serum samples. This study aims to test the new point-of-care devices that are designed to be low cost and user-friendly.

Excess, stored, HCV patients' plasma, serum and blood samples will be supplied by the Virology laboratory (Hull University Teaching Hospital's Trust; HUTH). These samples were taken and analysed as part of patients' clinical monitoring, and are stored prior to disposal in the Virology laboratory. The proposed study will use the samples in a fully anonymised manner.


Eligibility criteria: Inclusion Criteria:

* Blood sample taken

Exclusion Criteria:

* None

Primary outcomes:
measure: Validation of Microfluidic device with serum and plasma
timeFrame: 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Kingston upon Hull
country: United Kingdom
facility: University of Hull
Study officials:
References:
Clinical trial NCT04407975: Effect of Single Dose Antenatal Betamethasone on Neonatal Respiratory Morbidity After Elective Cesarean
Official title: Effect of Single Dose Antenatal Betamethasone on the Incidence of Neonatal Respiratory Morbidity After Elective Cesarean Section at Term: A Prospective Double Blinded Placebo Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Respiratory Morbidity
Lead sponsor: Makassed General Hospital
Sponsor class: OTHER
First posted: 2020-05-29
Enrollment: 400
Sex: FEMALE
Minimum age (years): 17
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Patients undergoing elective C-section will be randomized into two groups. The first group will receive one dose of Betamethasone at least 24 hours before scheduled C-section. The second group will receive placebo.

Detailed description: This is a prospective double blinded randomized clinical trial. Patients will be randomized into two groups. Group A will receive one dose of Betamethasone at least 24 hours before scheduled C-section. Group B will receive placebo. The maternal and neonatal outcomes will be studied in order to assess the effect of Betamethasone on respiratory morbidity of the newborn infant.

Eligibility criteria: Inclusion Criteria:

* women with singleton or multiple gestation,
* between 37 and 40 weeks of pregnancy (as calculated from the first day of the last menstrual period)

Exclusion Criteria:

* any medical problem that could affect fetal well-being;
* evidence of intrauterine infection,
* oligohydramnios,
* fetal congenital malformations,
* preeclampsia,
* maternal hypertension,
* severe fetal rhesus sensitization,
* antepartum hemorrhage,
* Intrauterine growth restriction
* preterm rupture of membranes
* preterm delivery
* previously received antenatal steroids less than one month ago
* those who decline to participate in the study.

Primary outcomes:
measure: Percentage of patients with respiratory morbidity
timeFrame: at birth
Secondary outcomes:
measure: Admission to Neonatal Intensive Care Unit (NICU)
timeFrame: up to 2 weeks
Other outcomes:
Locations:
city: Beirut
country: Lebanon
facility: Makassed General Hospital
Study officials:
affiliation: Makassed General Hospital
name: Manal Hubeish, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00147875: Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma
Official title: PVAG - Phase I/II Dose Finding Trial in Elderly Patients (> 60 Years) With Advanced Stages Hodgkin's Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Hodgkin's Disease
Keywords: Lymphoma
Gemcitabine
Advanced stages Hodgkin's lymphoma
Elderly
Lead sponsor: University of Cologne
Sponsor class: OTHER
Collaborators: name: German Hodgkin's Lymphoma Study Group
name: Eli Lilly and Company
First posted: 2005-09-07
Enrollment: 60
Sex: ALL
Minimum age (years): 60
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objectives of this study are to assess the feasibility and efficacy of a combination chemotherapy (PVAG) in elderly patients with advanced stages Hodgkin's lymphoma.

Detailed description: Gemcitabine shows promising activity in patients with relapsed lymphoma either administered as single agent or in combination with other cytotoxic agents. No trial to date evaluated its role in patients with primary Hodgkin's lymphoma. We therefore developed a three-weekly regimen based on the standard ABVD regimen.

Eligibility criteria: Inclusion Criteria:

* Hodgkin's lymphoma (histologically proven)
* Clinical stage IIB (with risk factors bulky mediastinal mass and/or extranodal involvement), III, or IV
* No prior antitumor therapy
* Age 60 to 75 years
* WHO performance status 0-2
* Normal pulmonary function
* Written informed consent

Exclusion Criteria:

* The following histologies are excluded: lymphocyte predominant HD
* Leukocytes \< 2,500/microL
* Platelets \< 100,000/microL

Primary outcomes:
measure: Phase I: Dose-limiting toxicities and dose reductions
measure: Phase II: Treatment administration and complete response rate
Secondary outcomes:
measure: Toxicities
measure: Supportive care (RBCT need, antibiotic need)
measure: Early progression rate
measure: Overall survival
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: University of Cologne
state: NRW
Study officials:
affiliation: University of Cologne
name: Andreas Engert
role: PRINCIPAL_INVESTIGATOR
References:
citation: Boll B, Bredenfeld H, Gorgen H, Halbsguth T, Eich HT, Soekler M, Markova J, Keller U, Graeven U, Kremers S, Geissler M, Trenn G, Fuchs M, von Tresckow B, Eichenauer DA, Borchmann P, Engert A. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011 Dec 8;118(24):6292-8. doi: 10.1182/blood-2011-07-368167. Epub 2011 Sep 13.